Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
Multiple Myeloma (MM) is a hematologic malignancy characterized by clonal plasma cell development, leading to serious complications. Despite traditional treatments, MM remains incurable, necessitating innovative therapeutic approaches. Chimeric Antigen Receptor (CAR) T-cell therapy and Bispecific T-...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2025-01-01
|
| Series: | Iranian Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://ijms.sums.ac.ir/article_50407_ad2eaf591bada72e1e5d479cee299d69.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859162002489344 |
|---|---|
| author | Rahul Navab Pragyat Futela Verkha Kumari Jayesh Valecha Ramansh Bandhu Gupta Rohit Jain |
| author_facet | Rahul Navab Pragyat Futela Verkha Kumari Jayesh Valecha Ramansh Bandhu Gupta Rohit Jain |
| author_sort | Rahul Navab |
| collection | DOAJ |
| description | Multiple Myeloma (MM) is a hematologic malignancy characterized by clonal plasma cell development, leading to serious complications. Despite traditional treatments, MM remains incurable, necessitating innovative therapeutic approaches. Chimeric Antigen Receptor (CAR) T-cell therapy and Bispecific T-cell engagers (BiTEs) are emerging immunotherapies showing promise in MM treatment. CAR T-cell therapy involves modifying patient T-cells to target specific antigens, primarily B Cell Maturation Antigen (BCMA). BiTEs, on the other hand, are non-IgG-like bispecific antibodies designed to engage both CD3 and tumor-associated antigens. These therapies exhibit impressive efficacy in clinical trials, leading to FDA approvals for specific MM patient populations. Despite their successes, these therapies come with unique challenges and adverse effects, such as cytokine release syndrome (CRS) and neurotoxicity. This narrative review explores the mechanisms, efficacy, challenges, and potential benefits of CAR T-cell and BiTE therapies for MM patients, shedding light on their roles in addressing this complex disease. |
| format | Article |
| id | doaj-art-26c68387f3a541f480912f2eaae5476a |
| institution | Kabale University |
| issn | 0253-0716 1735-3688 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Shiraz University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Medical Sciences |
| spelling | doaj-art-26c68387f3a541f480912f2eaae5476a2025-02-11T07:30:13ZengShiraz University of Medical SciencesIranian Journal of Medical Sciences0253-07161735-36882025-01-0150111010.30476/ijms.2024.101739.344650407Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing TreatmentRahul Navab0Pragyat Futela1Verkha Kumari2Jayesh Valecha3Ramansh Bandhu Gupta4Rohit Jain5PES Institute of Medical Sciences and Research, Kuppam, IndiaMayo Clinic, Rochester, MN, United States of AmericaLiaquat National Hospital & Medical College, Karachi, PakistanIndira Gandhi Medical College and Hospital, Shimla, IndiaUniversity College of Medical Sciences, New Delhi, IndiaPenn State Health Milton S. Hershey Medical Center, Pennsylvania, United States of AmericaMultiple Myeloma (MM) is a hematologic malignancy characterized by clonal plasma cell development, leading to serious complications. Despite traditional treatments, MM remains incurable, necessitating innovative therapeutic approaches. Chimeric Antigen Receptor (CAR) T-cell therapy and Bispecific T-cell engagers (BiTEs) are emerging immunotherapies showing promise in MM treatment. CAR T-cell therapy involves modifying patient T-cells to target specific antigens, primarily B Cell Maturation Antigen (BCMA). BiTEs, on the other hand, are non-IgG-like bispecific antibodies designed to engage both CD3 and tumor-associated antigens. These therapies exhibit impressive efficacy in clinical trials, leading to FDA approvals for specific MM patient populations. Despite their successes, these therapies come with unique challenges and adverse effects, such as cytokine release syndrome (CRS) and neurotoxicity. This narrative review explores the mechanisms, efficacy, challenges, and potential benefits of CAR T-cell and BiTE therapies for MM patients, shedding light on their roles in addressing this complex disease.https://ijms.sums.ac.ir/article_50407_ad2eaf591bada72e1e5d479cee299d69.pdfmultiple myelomacar t-cell therapybispecific antibodiesimmunotherapy |
| spellingShingle | Rahul Navab Pragyat Futela Verkha Kumari Jayesh Valecha Ramansh Bandhu Gupta Rohit Jain Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment Iranian Journal of Medical Sciences multiple myeloma car t-cell therapy bispecific antibodies immunotherapy |
| title | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment |
| title_full | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment |
| title_fullStr | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment |
| title_full_unstemmed | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment |
| title_short | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment |
| title_sort | advancing multiple myeloma immunotherapy a review of chimeric antigen receptor t cell and bispecific t cell engagers cell therapies in revolutionizing treatment |
| topic | multiple myeloma car t-cell therapy bispecific antibodies immunotherapy |
| url | https://ijms.sums.ac.ir/article_50407_ad2eaf591bada72e1e5d479cee299d69.pdf |
| work_keys_str_mv | AT rahulnavab advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment AT pragyatfutela advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment AT verkhakumari advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment AT jayeshvalecha advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment AT ramanshbandhugupta advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment AT rohitjain advancingmultiplemyelomaimmunotherapyareviewofchimericantigenreceptortcellandbispecifictcellengagerscelltherapiesinrevolutionizingtreatment |